Increased Emotional-motivational Processing in Patients with Chronic Pain and Its Neural Correlates
NCT ID: NCT05257356
Last Updated: 2025-02-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
138 participants
INTERVENTIONAL
2022-04-06
2024-04-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Changes in Affective Pain Processing in Human Volunteers
NCT04280796
The Role of Sensory Processing Sensitivity in Pediatric Chronic Pain
NCT04473014
Eye Movement Desensitization and Reprocessing (EMDR) in Non-specific Chronic Back Pain
NCT01850875
Differences in Pain Processing Between Men and Women
NCT05031286
Pain Inhibition and Facilitation in Recurrent Low Back Pain
NCT03463759
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The perception of pain is multidimensional: The International Association for the Study of Pain (IASP) defines pain as "an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage", highlighting the crucial point that pain always comprises emotional components. Specifically, pain comprises sensory-discriminative, emotional-motivational and cognitive-evaluative components as initially proposed in Melzack's tripartite model of pain. Typically, the sensory-discriminative and emotional-motivational components are well aligned; but these components can dissociate. For example, many people find a painful massage pleasant or enjoy eating hot chilies, likely through a reappraisal of the painful sensation. Extreme examples are prefrontal lobotomy, cingulotomy or strong morphine analgesia where pain is still recognized in its sensory-discriminative dimension, but loses its aversiveness and threat. Such a loss of emotional-motivational pain components can lead to severe injuries and life-threatening conditions. Although these examples affect only very few people, they illustrate a conceptually important point: Emotional-motivational aspects are the driving force in pain.
The dissociation of pain components: As described above and as an idea inherent to Melzack's tripartite model of pain, the different pain components can dissociate. The underlying mechanisms how such a dissociation can develop and be maintained are largely unclear. Based on earlier findings, operant and associative learning mechanisms appear to be likely candidates.
Applying the mechanisms of associative conditioning, a counterconditioning experiment showed impressively a dissociation between sensory-discriminative and emotional-motivational pain components. Counterconditioning is a specific form of classical conditioning used to reduce negative stimulus valence through a new association between a behavior and a stimulus of an oppositive valence. For example, Eroféeva applied this principle in the context of pain, pairing a positive stimulus (food) with an aversive painful stimulus in dogs. The appetitive response to the positive stimulus gradually and completely replaced aversive pain responses, suggesting that the pain lost its aversiveness, thus diminishing its emotional-motivational component. However, since the dogs still utilized the painful stimulus to predict the rewarding stimulus, sensory-discriminative pain components must have been preserved. This example illustrates that learning might be a mechanism underlying a gradual dissociation of sensory-discriminative and emotional-motivational pain components.
The negative hedonic shift in chronic pain: In line with the observation that learning related to a dissociation of different pain components can be altered, emotional-motivational components appear to dominate over sensory-discriminative components in chronic pain. For example, the influential Fear-Avoid-ance Model of Pain termed chronic pain as "exaggerated pain perception" in its earliest version, because of disproportionally augmented emotional-motivational relative to sensory-discriminative pain components. Such increased emotional-motivational pain perception is often reflected in chronic pain patients in heightened pain aversiveness and pain avoidance behavior. Further and in line with such increases, recent findings suggest that pain processing is characterized by a functional shift from nociceptive to non-nociceptive emotional brain circuits in chronic pain, specifically to fronto-striatal circuits. Such a shift in chronic pain fits the observation of augmented negative affect and impaired motivated behavior, mirrored in anhedonia (i.e. the inability to feel pleasure) and very high comorbidity (up to 86%) between chronic pain and affective disturbances. Based on such observations, chronic pain has been described to induce a negative hedonic shift. Although this suggestion has been cited often and is compelling in explaining the development and maintenance of unspecific chronic pain, the underlying mechanisms of such a shift have not directly been investigated so far. It has been shown that patients with constant chronic back pain have increased activation in the medial prefrontal cortex (mPFC) and in the amygdala, as well as an increased incidence of white matter and increased functional connections between the mPFC, the nucleus accumbens (NAcc) and the amygdala compared to recovered patients and healthy controls. Of particular importance, altered fronto-striatal circuits, especially the increased functional connectivity between the NAcc and ventromedial prefrontal cortex (vmPFC), predicts the transition from subacute to chronic pain. Moreover, the importance of the NAcc-vmPFC connectivity for the modulation of pain perception has been confirmed in healthy persons.
The aims of this study are therefore (1) to illustrate that emotional-motivational components are in-creased relative to sensory-discriminative components in chronic pain, (2) to show that increased emo-tional motivational pain responses in chronic pain can also be decreased by counterconditioning, leading to a normalization of pain perception relative to healthy individuals as well, and (3) to assess the neural correlate of the counterconditioning effects on emotional-motivational pain responses, specifically alterations in functional connectivity yin fronto-striatal networks.
Intended intervention: All participants perform one psychophysical task to assess sensory-discriminative and emotional-motivational pain responses simultaneously. In Substudy 1 an associative learning paradigm will be implemented to dissociating the sensory-discriminative pain responses compared to emotional-motivational pain responses by monetary reinforcement. In Substudy 2, the effects of the counterconditioning on fronto-striatal networks will be assessed by MRI.
Potential for new scientific generalizable knowledge: Our knowledge on the basic mechanisms of pain increased rapidly in recent years. Nevertheless, treatment of chronic pain is surprisingly unsuc-cessful. Particularly, patients suffering from unspecific pain often do not get efficient treatment. This gap between basic knowledge and applied treatment likely is caused by a mismatch between research foci and the subjective complains of patients. Basic research focuses on neurobiological basic mechanisms, e.g. on molecular and neuronal levels. Although indisputable of high relevance for our understanding of pian, it is hard to transfer these basic mechanisms directly to the multifaceted experience of pain in humans, because this can be strongly modulated by emotional and cognitive processes. The goal of this study is to provide a substantial contribution to lose this gap by (1) providing new methods needed for an appropriate investigation of the problem outlined and (2) by gathering new knowledge on pain mechanisms relevant in the development and maintenance of chronic pain.
This study is a Clinical Study Category A because it includes an intervention that is neither a drug nor a transplant. The risk for the participants is minimal.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
Substudy 2: As in Substudy 1, all participants will perform one psychophysical task to assess sensory-discriminative and emotional-motivational pain responses simultaneously combined with MRI assessing the effects of the counterconditioning on fronto-striatal circuits.
BASIC_SCIENCE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Chronic Pain Patients
All participants perform 1 psychophysical task to assess sensory-discriminative and emotional-motivational pain responses simultaneously. The performance of chronic pain patients will be compared to healthy volunteers to characterize possible alterations in patients. Associative learning by monetary reinforcement will be implemented to diminish the aversiveness of pain, which is assumed to be already increased in patients.
Primary objectives: Show that emotional-motivational components are increased relative to sensory-discriminative components in chronic pain, and that enhanced emotional-motivational pain responses in chronic pain can be decreased by counterconditioning, leading to a normalization of pain perception relative to healthy individuals.
Secondary objective: Assess whether chosen personality traits assessed by questionnaires can explain variations in sensory-discriminative and emotional-motivational pain responses.
psychophysical tasks
Substudy 1(b): All participants will perform one psychophysical task to assess sensory-discriminative and emotional-motivational pain responses simultaneously. The responses and the reaction times of chronic pain patients will be compared to those of healthy participants to characterize possible alterations in the patients (Substudy 1). Associative learning by monetary reinforcement will be implemented to diminish the aversiveness of the pain, which is assumed to be already increased in the patients.
Substudy 2: As in Substudy 1, all participants will perform one psychophysical task to assess sensory-discriminative and emotional-motivational pain responses simultaneously combined with MRI assessing the effects of the counterconditioning on fronto-striatal circuits.
Healthy Controls
Substudy 1(b): Participants perform 1 psychophysical task to assess sensory-discriminative and emotional-motivational pain responses simultaneously. Associative learning by monetary reinforcement is implemented to diminish the pain aversiveness. Substudy2: Participants perform the same task combined with MRI assessing the counterconditioning effects on frontostriatal circuits.
Primary objective: Show that emotional-motivational components are increased relative to sensory-discriminative components in chronic pain (Substudy 1(b)). Assess the neural correlates of the counterconditioning effects on emotional-motivational pain responses, specifically alterations in functional connectivity in frontostriatal networks compared to the unchanged natural state (Substudy 2).
Secondary objective: To assess whether chosen personality traits assessed by questionnaires can explain variations in sensory-discriminative and emotional-motivational pain responses (Substudy1(b)+2).
psychophysical tasks
Substudy 1(b): All participants will perform one psychophysical task to assess sensory-discriminative and emotional-motivational pain responses simultaneously. The responses and the reaction times of chronic pain patients will be compared to those of healthy participants to characterize possible alterations in the patients (Substudy 1). Associative learning by monetary reinforcement will be implemented to diminish the aversiveness of the pain, which is assumed to be already increased in the patients.
Substudy 2: As in Substudy 1, all participants will perform one psychophysical task to assess sensory-discriminative and emotional-motivational pain responses simultaneously combined with MRI assessing the effects of the counterconditioning on fronto-striatal circuits.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
psychophysical tasks
Substudy 1(b): All participants will perform one psychophysical task to assess sensory-discriminative and emotional-motivational pain responses simultaneously. The responses and the reaction times of chronic pain patients will be compared to those of healthy participants to characterize possible alterations in the patients (Substudy 1). Associative learning by monetary reinforcement will be implemented to diminish the aversiveness of the pain, which is assumed to be already increased in the patients.
Substudy 2: As in Substudy 1, all participants will perform one psychophysical task to assess sensory-discriminative and emotional-motivational pain responses simultaneously combined with MRI assessing the effects of the counterconditioning on fronto-striatal circuits.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Good overall health status
* Sufficient knowledge of German or English to follow instructions
* Ability to give written informed consent
* Between 18 and 70 years of age
* Unspecific musculoskeletal pain as defined according to the ICD-11 as chronic primary pain (MG30.1, e.g. chronic widespread pain, complex regional pain syndrome, chronic primary headache or orofacial pain, chronic migraine, chronic tension-type headache, trigeminal autonomic cephalalgias, burning mouth syndrome, chronic primary visceral pain, irritable bowel syndrome, chronic primary musculoskeletal pain), and which is not classified as chronic cancer related pain (MG30.2; e.g. chronic cancer pain, chronic post-cancer treatment pain), chronic postsurgical or post traumatic pain (MG30.3; e.g. chronic postsurgical pain, chronic posttraumatic pain), chronic secondary musculoskeletal pain (MG30.4; e.g. chronic musculoskeletal pain from persistent inflammation, chronic musculoskeletal pain associated with structural changes, chronic musculoskeletal pain associated with a disease of the nervous system), chronic secondary visceral pain (MG30.5; e.g. chronic visceral pain from persistent inflammation, chronic visceral pain from vascular mechanisms, chronic visceral pain from mechanical factors), chronic neuropathic pain (MG30.6; e.g. chronic peripheral neuropathic pain, trigeminal neuralgia, postherpetic neuralgia, chronic central neuropathic pain), chronic secondary headache or orofacial pain (MG30.7; e.g. chronic dental pain, chronic neuropathic orofacial pain, trigeminal neuralgia, headache or orofacial pain attributed to chronic secondary temporo-mandibular disorders), other specified chronic pain (MG30.Y), or other non-specified chronic pain (MG30.Z)
* Sufficient knowledge of German or English to follow instructions
* Ability to give written informed consent
Exclusion Criteria
* Major psychiatric or neurological disorders, and substance abuse
* Consumption of alcohol, illegal drugs, and analgesic drugs within 24 hours before testing
* Pregnancy
* For Substudy 2: An MR-specific safety questionnaire will be filled in to check for any contradiction to magnetic resonance imaging (MRI): wearing an electronic device, implants or prosthetics, injury from metal parts or fragments, metal parts in or on the body, surgery on the head, heart or back, tattoo or permanent makeup, problems lying still for long periods of time, claustrophobia, possible pregnancy, metal contraceptive coil
CHRONIC PAIN PATIENTS
* Major psychiatric or neurological disorders, and substance abuse
* Regular intake of opioids for pain (e.g. burprenorphine, codeine, fentanyl, hydromorphone, orphine, oxycodone, tapentadol, tilidine/na-loxone, tramadol)
* Consumption of alcohol, illegal drugs, and analgesic drugs within 24 hours before testing
* Pregnancy
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
SNSF
UNKNOWN
susanne becker
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
susanne becker
Head of Research Group
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Susanne Becker, Dr. Prof.
Role: PRINCIPAL_INVESTIGATOR
Balgrist Universitätsklinik
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Balgrist Campus
Zurich, Canton of Zurich, Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P000PS_203872/1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.